Axim develops rapid test for dry eye inflammatory biomarker

Axim Biotechnologies has developed a rapid quantitative tear test to detect an inflammatory biomarker for dry eye disease, according to a press release. Diagnosis and treatment of dry eye disease (DED) can be difficult because of the discordance between signs and...

AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations

SAN DIEGO – March 24, 2021 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s manufacturing partner,...